Science Board meeting
This article was originally published in The Tan Sheet
Executive SummaryFDA's Science Board will conduct a meeting on May 30 in Gaithersburg, Md., to discuss a subcommittee review of the National Center for Toxicological Research and Office of Regulatory Affairs, according to a May 1 Federal Register notice. The board will hear and discuss updates on a subcommittee review of the agency's science programs and infrastructure from Science Board meetings in June and December 2007, the notice says. The board will discuss keeping pace with technical and scientific evolutions in the fields of regulatory science. To request time for an oral presentation during the meeting, contact the Office of the Commissioner by May 15; to make written presentations to the board, information must be submitted by May 23...
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.